ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2026
[
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo investigate the effects of
methodsA mouse model of FA-induced renal fibrosis were treated daily with QSG at 4.0 g·kg
resultsThe mouse models of renal fibrosis showed increased renal expressions of α‑SMA, FN, HIF-1α, HK2, PFKM, PKM2, LDHA, Pan Kla, and H3K18la, elevated serum SCR and BUN and renal lactate level, and decreased E-cad expression. QSG treatment effectively reversed these changes and alleviated renal fibrosis in the mouse models. Immunofluorescence staining showed that QSG treatment significantly reversed the elevation of renal α‑SMA, FN and LDHA expressions and reduction of LDHA/H3K18la co-localization, and enhanced E-cad expression. In HK-2 cells, TGF‑β1 treatment significantly reduced cell viability, proliferation and OCR, and increased ECAR, lactate, α‑SMA, LDHA, and H3K18la, which were all reversed by treatment with QSG-medicated serum. Exogenous lactate obviously reversed the inhibitory effects of QSG on these proteins.
conclusionsQSG alleviates renal fibrosis in mice by modulating glycolytic reprogramming, reducing lactate accumulation, and inhibiting H3K18la.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.